Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.40 |
| ▸ | APLNR | P35414 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19853068 | 0.93 | APLNR (0.40) | ESR1ESR2APLNRLMNAHRH1 | |
| SCHEMBL20376381 | 0.90 | APLNR (0.38) | ESR1ESR2APLNRHRH1KCNH2 | |
| SCHEMBL18948514 | 0.90 | ESR1 (0.41) | ESR1ESR2APLNRHRH1KCNH2 | |
| SCHEMBL25898707 | 0.89 | APLNR (0.37) | ESR1ESR2APLNRNR1I2 | |
| SCHEMBL18672471 | 0.89 | APLNR (0.37) | ESR1ESR2APLNRNR1I2 | |
| SCHEMBL23871060 | 0.87 | APLNR (0.38) | ESR1ESR2APLNRNR1I2HRH1 | |
| SCHEMBL18596818 | 0.87 | APLNR (0.38) | ESR1ESR2APLNRNR1I2HRH1 | |
| SCHEMBL18948485 | 0.87 | APLNR (0.38) | ESR1ESR2APLNRNR1I2HRH1 | |
| SCHEMBL19523028 | 0.86 | ESR1 (0.46) | ESR1ESR2APLNRHRH1KCNH2 | |
| SCHEMBL22166120 | 0.84 | APLNR (0.36) | ESR1ESR2APLNRNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174553-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2023-06-08 | — | — | US | disclosed |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174553-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ESR1 3424/4885ESR2 1986/4885APLNR 4684/4885 |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | ESR1 964/4885ESR2 979/4885APLNR 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.